The proposed study is a prospective, single-center and open-ended study in patients over the age of 70 with treatment-naive diffuse large B-cell lymphoma (DLBCL). This study intends to explore a new treatment pattern using Pro-miniCHOP-like regimen and simultaneously evaluate its safety and efficacy for future clinical practice.
The study will start with an initial 21-days of induction therapy with combination of orelabrutinib, pomalidomide and rituximab(Pro regimen) in eligible patients, following contrast computed temography(CT) to guide the next treatment. Patients whose lesions have 25% or more reduction will next receive Pro-miniCHOP-like regimen for 6 cycles. Patients with reduction less than 25% will receive R-miniCHOP-like regimen also for 6 cycles. After that, maintenance therapy with pomalidomide for two years will be given to patients undergoing Pro-miniCHOP-like regimen.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
Rituximab 375mg/m2 ivgtt d1;
Orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity;
Pomalidomide 4mg d1-7 each cycle. After Phase II of treatment, single agent pomalidomide 4 mg d1-d7 in 21-day cycles for 2 years.
the First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
RECRUITINGOverall Response Rate(ORR) after Pro-miniCHOP-like regimen
The rate of patients who achieved complete response and partial response after Pro-miniCHOP-like regimen.
Time frame: At the end of cycle 6 (each cycle is 21 days)
Complete Response Rate(CRR) after Pro-miniCHOP-like regimen
The rate of patients who achieved complete response after Pro-miniCHOP-like regimen.
Time frame: At the end of cycle 6 (each cycle is 21 days)
Incidence of treatment-emergent adverse events, treatment-related adverse events and serious adverse events
The safety and tolerability of the therapeutic regimen measured by the incidence of Treatment-Emergent Adverse Events, Treatment-Related Adverse Events and Serious Adverse Events.
Time frame: Initiation of study drug until 28 days after last dose
Overall Response Rate(ORR) after Pro induction regimen
The rate of patients who achieved complete response and partial response after Pro induction regimen.
Time frame: At the end of a cycle 1 of induction therapy period (each cycle is 21 days)
Complete Response Rate(CRR) after Pro induction regimen
The rate of patients who achieved complete response after Pro induction regimen.
Time frame: At the end of a cycle 1 of induction therapy period (each cycle is 21 days)
Overall Survival (OS)
OS will be assessed from the first drug given to date of death or end of follow-up.
Time frame: Up to 2 years after the end of last patient's treatment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
rituximab 375mg/m2 ivgtt d1; orelabrutinib 150mg per day oral administration till progresses or intolerant toxicity; pomalidomide 4mg d1-7; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
rituximab 375mg/m2 ivgtt d1; cyclophosphamide 400mg/m2 ivgtt d2; doxorubicin 25mg/m2 ivgtt d2/ doxorubicin liposome 15 mg/m2 ivgtt d2; vindesine 2mg ivgtt d2; dexamethasone 10mg ivgtt d2-6.
Progression Free Survival (PFS)
PFS will be assessed from the first drug given to date of progression, relapse, death or end of follow-up.
Time frame: Up to 2 years after the end of last patient's treatment